Turnover: 1.817 million EUR (2017)
Country: France
CellNovo is an independent medical technology company specializing in diabetes, having developed and commercialized an innovative connected mobile diabetes management system that improves patients' lives. The CellNovo insulin pump features an on-screen mobile control device and an integrated blood glucose meter. This connected platform consists of a dedicated Android smartphone that communicates via Bluetooth with the micro insulin pump. CellNovo has sold 1,159 systems since its launch.
The company went into receivership in 2019
Financial Data
DUNS: 808426662
Legal Name: CELLNOVO GROUP
Address: 6 RUE DE TEHERAN , 75008 PARIS 8
Number of employees: Entre 20 et 49 salariés (2018)
Capital: 17 641 765
Financial Data:
| Year | Turnover (€) | Net Profit (€) | Fiscal Year End | Fiscal Year Duration |
|---|---|---|---|---|
| 2017 | 1 817 044 EUR | -3 732 877 EUR | 31/12/2017 | 12 |
| 2016 | 1 456 060 EUR | -3 693 992 EUR | 31/12/2016 | 12 |
| 2015 | 37 840 EUR | -2 705 693 EUR | 31/12/2015 | 12 |
Studies mentioning this company
The Insulin Pump Market - France
Other companies mentioned:
- Medtronic
- Cellnovo
- Roche Diabetes Care (Roche Groupe)
- Insulet
- Ypsomed Group
- ISIS diabète (Isis Médical)
- Physidia
- Nova Medical Center
- Medtrum
- Apex Wellell
- Open APS
- Eli Lilly
- TreeFrog Therapeutics
- Boydsense
- Diabeloop